Denosumab is not associated with risk of malignancy? More evidence is needed

Autor:	H Qiu, Yanming Lin, Jiasong Zhao
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Risk of malignancy MEDLINE Zoledronic Acid Rheumatology Denosumab Zoledronic acid Neoplasms Internal medicine medicine Humans business medicine.drug
Zdroj:	Osteoporosis International. 32:2133-2134
ISSN:	1433-2965 0937-941X
DOI:	10.1007/s00198-021-05988-2
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b29476bf55388134c12360484aa82d86 https://doi.org/10.1007/s00198-021-05988-2 Zobrazit plný text záznamu Full text from SpringerLink